Actuate Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Actuate Therapeutics Q1 net loss narrows 10.94% to $5.63 million

Actuate Therapeutics Inc expected to post a loss of 22 cents a share - Earnings Preview

Analysts Are Bullish on These Healthcare Stocks: Actuate Therapeutics, Inc. (ACTU), Agios Pharma (AGIO)

Actuate Therapeutics receives FDA clearance for oral elraglusib study

Actuate Therapeutics adds Martin Huber to board of directors

Actuate Therapeutics wins FDA IND clearance for oral elraglusib cancer trial

Actuate Therapeutics Inc - FDA Clears Ind for Phase 1/2 Study of Oral Elraglusib in Advanced Cancer Patients

Actuate Therapeutics Inc - Elraglusib Plus Ras Inhibitor Preclinical Results Expected in Mid-2026

Actuate Therapeutics Announces FDA Clearance of Ind for Oral Elraglusib and Strategic Initiatives to Advance the Elraglusib Development Program

Press Release: Actuate Therapeutics Announces FDA Clearance of IND for Oral Elraglusib and Strategic Initiatives to Advance the Elraglusib Development Program

Actuate Therapeutics director Martin H. Huber Jr files initial beneficial ownership statement

Actuate Therapeutics Adds Oncology Expert to Board Leadership

Actuate Therapeutics names Martin Huber to board as independent director

Press Release: Actuate Therapeutics Announces Key Appointment of Industry Veteran to Board of Directors

Actuate Therapeutics Price Target Maintained With a $15.00/Share by HC Wainwright & Co.

Health Rounds: Actuate Therapeutics drug improves survival odds in pancreatic cancer trial

B. Riley Cuts Actuate Therapeutics Price Target to $8 From $20, Maintains Buy Rating

Actuate says elraglusib plus chemo lifts median survival 40% in phase 2 pancreatic trial